SPI Pharma

spipharma.com

For over 75 years, we have supplied the pharmaceutical industry with highly engineered products and innovative solutions that improve the formulation and delivery of drug products to meet patient needs. Our functional excipients and active ingredients meet the highest-quality standards possible and can offer customized, cost-effective options for many applications.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS, PHARMACY MARKET

AQUESTIVE THERAPEUTICS EXPANDS LICENSE AND SUPPLY AGREEMENT WITH PHARMANOVIA FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM TO ADDITIONAL GLOBAL MARKETS

Globenewswire | March 30, 2023

news image

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has expanded its exclusive license and supply agreement with Atnahs Pharma UK Limited (“Pharmanovia”), a global pharmaceutical company that revitalizes, extends and expands the lifecycle of established medicines, for Libervant™ Buccal Film to cover the rest ...

Read More

BUSINESS INSIGHTS, PHARMA TECH

ENDO ANNOUNCES AGREEMENT WITH SLAYBACK PHARMA TO DISTRIBUTE PREVDUO™ THE FIRST AND ONLY FDA-APPROVED NEOSTIGMINE-GLYCOPYRROLATE COMBINATION

prnewswire | April 28, 2023

news image

Endo International plc announced that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. have executed an agreement with Slayback Pharma LLC to distribute Slayback's Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe on an exclusive basis in the U.S. The U.S. Food and Drug Administration (FDA) approved Prevduo™ in February 2023 for the reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after sur...

Read More

BUSINESS INSIGHTS

POSTERA SPEARHEADS AI-DRIVEN DRUG DISCOVERY COLLABORATION TO DEVELOP ANTIVIRAL THERAPEUTICS WITH INITIAL $68M IN NIH FUNDING

PostEra | May 19, 2022

news image

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The center will receive initial funding of $68M. PostEra co-leads this initiative with the Drugs for Neglected Diseases Initiative, a global charity with expertise in drug development for global equitable access, and the Memorial Sloan Kettering Cancer Ce...

Read More

VIEWS AND ANALYSIS

ENTERIS BIOPHARMA PUBLISHES WHITE PAPER EXAMINING FACTORS TO CONSIDER WHILE EVALUATING ORAL ADMINISTRATION OF PEPTIDES

Enteris BioPharma | September 13, 2022

news image

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation announced the publication of a new white paper in Drug Development & Delivery entitled, "Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration." The paper, authored by John Vrettos, PhD, Director of Formulation Developmen...

Read More
news image

BUSINESS INSIGHTS, PHARMACY MARKET

AQUESTIVE THERAPEUTICS EXPANDS LICENSE AND SUPPLY AGREEMENT WITH PHARMANOVIA FOR LIBERVANT™ (DIAZEPAM) BUCCAL FILM TO ADDITIONAL GLOBAL MARKETS

Globenewswire | March 30, 2023

Aquestive Therapeutics, Inc. a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced it has expanded its exclusive license and supply agreement with Atnahs Pharma UK Limited (“Pharmanovia”), a global pharmaceutical company that revitalizes, extends and expands the lifecycle of established medicines, for Libervant™ Buccal Film to cover the rest ...

Read More
news image

BUSINESS INSIGHTS, PHARMA TECH

ENDO ANNOUNCES AGREEMENT WITH SLAYBACK PHARMA TO DISTRIBUTE PREVDUO™ THE FIRST AND ONLY FDA-APPROVED NEOSTIGMINE-GLYCOPYRROLATE COMBINATION

prnewswire | April 28, 2023

Endo International plc announced that its subsidiaries Endo Ventures Limited and Par Pharmaceutical, Inc. have executed an agreement with Slayback Pharma LLC to distribute Slayback's Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe on an exclusive basis in the U.S. The U.S. Food and Drug Administration (FDA) approved Prevduo™ in February 2023 for the reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after sur...

Read More
news image

BUSINESS INSIGHTS

POSTERA SPEARHEADS AI-DRIVEN DRUG DISCOVERY COLLABORATION TO DEVELOP ANTIVIRAL THERAPEUTICS WITH INITIAL $68M IN NIH FUNDING

PostEra | May 19, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced a multi-year collaboration with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. The center will receive initial funding of $68M. PostEra co-leads this initiative with the Drugs for Neglected Diseases Initiative, a global charity with expertise in drug development for global equitable access, and the Memorial Sloan Kettering Cancer Ce...

Read More
news image

VIEWS AND ANALYSIS

ENTERIS BIOPHARMA PUBLISHES WHITE PAPER EXAMINING FACTORS TO CONSIDER WHILE EVALUATING ORAL ADMINISTRATION OF PEPTIDES

Enteris BioPharma | September 13, 2022

Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation announced the publication of a new white paper in Drug Development & Delivery entitled, "Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration." The paper, authored by John Vrettos, PhD, Director of Formulation Developmen...

Read More